-
Electronic (PDF)
-
Site License
-
Enterprisewide
Ranbaxy Laboratories Limited (500359) - Financial and Strategic SWOT Analysis Review
GlobalData, May 2011, Pages: 38
Ranbaxy Laboratories Limited (500359) - Financial and Strategic SWOT Analysis Review
Summary
Ranbaxy Laboratories Limited (Ranbaxy) is engaged in the manufacturing, marketing and distribution of pharmaceutical ingredients. The product portfolio of the company includes Simvastatin, CoAmoxyclav, inter alia, Amoxycillin, Ciprofloxacin, Isotretinon and Cephalexin. The major markets of the company’s products include India, the US, Europe, Russia, South Africa and Brazil. The company’s manufacturing facilities are located in various nations, namely, China, India, Brazil, Malaysia, Nigeria, Ireland, Japan, Romania, South Africa, Vietnam and the US. It serves customers in over 125 countries worldwide. Ranbaxy holds a research and development facility in Gurgaon, New Delhi, India. Ranbaxy is headquartered at Gurgaon in Haryana, India.
Ranbaxy Laboratories Limited Key Recent Developments…
Jan 31, 2011: Ranbaxy, Government Of Yaroslavl Region, Russia Sign MoU In Healthcare And Medical Science
Sep 01, 2010: Ranbaxy Opens New Manufacturing Facility In South Africa
Aug 12, 2010: Ranbaxy Announces Senior Management Changes
Jul 21, 2010: Daiichi Sankyo To Leverage Ranbaxy’s Network To Market Tavanic In Romania And South Africa
Jul 02, 2010: Daiichi Sankyo And Ranbaxy To Integrate New Drug Research And Development System
This comprehensive SWOT profile of Ranbaxy Laboratories Limited provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
List of Tables
List of Figures
Section 1 - About the Company
Ranbaxy Laboratories Limited - Key Facts
Ranbaxy Laboratories Limited - Key Employees
Ranbaxy Laboratories Limited - Key Employee Biographies
Ranbaxy Laboratories Limited - Major Products and Services
Ranbaxy Laboratories Limited - Pharmaceutical Pipeline Products Data
Ranbaxy Laboratories Limited, Pipeline Products by Therapy Area
Ranbaxy Laboratories Limited, Pipeline Products by Development Phase
Ranbaxy Laboratories Limited - History
Ranbaxy Laboratories Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Ranbaxy Laboratories Limited - Business Description
Ranbaxy Laboratories Limited - SWOT Analysis
SWOT Analysis - Overview
Ranbaxy Laboratories Limited - Strengths
Strength - Strong Research and Development
Strength - Growth Prospects
Strength - Extensive Product Portfolio
Ranbaxy Laboratories Limited - Weaknesses
Weakness - Increased Operational Cost
Weakness - Involvement in Legal Actions
Ranbaxy Laboratories Limited - Opportunities
Opportunity - Emerging Markets
Opportunity - Changing Demographics
Ranbaxy Laboratories Limited - Threats
Threat - Intense Competition
Threat - Product Liability Claims
Threat - Government Regulations
Ranbaxy Laboratories Limited - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ranbaxy Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Ranbaxy Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Ranbaxy Laboratories Limited, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 31, 2011: Ranbaxy, Government Of Yaroslavl Region, Russia Sign MoU In Healthcare And Medical Science
Sep 01, 2010: Ranbaxy Opens New Manufacturing Facility In South Africa
Aug 12, 2010: Ranbaxy Announces Senior Management Changes
Jul 21, 2010: Daiichi Sankyo To Leverage Ranbaxy’s Network To Market Tavanic In Romania And South Africa
Jul 02, 2010: Daiichi Sankyo And Ranbaxy To Integrate New Drug Research And Development System
Jun 08, 2010: Ranbaxy Launches Generic Atorvastatin, ‘lipogen’, A Cholesterol-Reducing Medication In South Africa
May 21, 2010: Ranbaxy Launches Atorvastatin, Cholesterol-Reducing Medication Into The Canadian Healthcare System
Mar 29, 2010: Ranbaxy To Develop Biosimilar Therapeutic Protein In Collaboration With Pfenex
Mar 29, 2010: Syncom Healthcare Plans For New Contract Manufacturing Agreements
Mar 29, 2010: Ranbaxy Partners With Pfenex For Development Of Biosimilar Therapeutic Protein
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer
Ankur Drugs and Pharma Ltd.
GlaxoSmithKline Pharmaceuticals Limited
Abbott India Limited
Dr. Reddy's Laboratories Limited
Novartis India Limited
IPCA Laboratories Limited
Sun Pharmaceutical Industries Limited
Morepen Laboratories Limited
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
